Emerging applications of tumour-educated platelets in the detection and prognostication of ovarian cancer

References

[1] Antunes-Ferreira M, Koppers-Lalic D, Würdinger T. Circulating platelets as liquid biopsy sources for cancer detection. Mol Oncol 2021;15:1727–1743.

[2] Veld SGJG, Arkani M, Post E et al. Detection and localization of early- and late-stage cancers using platelet RNA. Cancer Cell 2022;40:999–1009.e6.

[3] Chen L, Wang K, Li L et al. Plasma exosomal miR-1260a, miR-7977 and miR-192-5p as diagnostic biomarkers in epithelial ovarian cancer. Future Oncol 2022;18:2919–2931.

[4] Dovizio M, Ballerini P, Fullone R et al. Multifaceted functions of platelets in cancer: from tumorigenesis to liquid biopsy tool and drug delivery system. Int J Mol Sci 2020;21:9585.

[5] Gao Y, Liu CJ, Li HY et al. Platelet RNA enables accurate detection of ovarian cancer: an intercontinental, biomarker identification study. Protein Cell 2022.

[6] Giannakeas V. Trends in platelet count among cancer patients. Exp Hematol Oncol 2022;11:16.

[7] Liu CJ, Li HY, Gao Y et al. Platelet RNA signature independently predicts ovarian cancer prognosis by deep learning neural network model. Protein Cell 2022.

[8] Lomnytska M, Pinto R, Becker S et al. Platelet protein biomarker panel for ovarian cancer diagnosis. Biomark Res 2018;6:2.

[9] Passiglia F, Rizzo S, Di Maio M et al. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis [published correction appears in Sci Rep. 2018 Nov 19;8(1):17270]. Sci Rep 2018;8:13379.

[10] Piek J, In ’t Veld S, Best M et al. EP457 assessment of ovarian tumors with tumor-educated platelets (TEPs). Int J Gynecol Cancer 2019;29:A291.

[11] Psaila B, Wang G, Rodriguez-Meira A et al.; NIH Intramural Sequencing Center. Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets. Mol Cell 2020;78:477–492.e8.

[12] Sabatier R, Garnier S, Guille A et al. Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial. Front Oncol 2022;12:946257.

[13] Siegel RL, Miller KD, Fuchs HE et al. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:7–33.

[14] Sol N, Wurdinger T. Platelet RNA signatures for the detection of cancer. Cancer Metastasis Rev 2017;36:263–272.

[15] Stone R, Nick A, McNeish I et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366:610–618.

[16] Wang T, Gao Y, Wang Xi et al. Establishment of an optimized CTC detection model consisting of EpCAM, MUC1 and WT1 in epithelial ovarian cancer and its correlation with clinical characteristics. Chin J Cancer Res 2022;34:95–108.

[17] Zhu JW, Charkhchi P, Akbari MR. Potential clinical utility of liquid biopsies in ovarian cancer. Mol Cancer 2022;21:114.

RIGHTS & PERMISSIONS

2023 The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.